CYTK
Cytokinetics, Incorporated · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cytokinetics.com
- Employees(FY) 409
- ISIN US23282W6057
Performance
-8.47%
1W
-5.93%
1M
-14.78%
3M
-19.71%
6M
-7.67%
YTD
-34.04%
1Y
Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Technical Analysis of CYTK 2025-03-07
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-03-03 03:00
Cytokinetics to Participate in March Investor Conferences(Globenewswire)
- 2025-02-27 22:00
Q4 2024 Cytokinetics Inc Earnings Call(Yahoo Finance)
- 2025-02-27 13:35
- 2025-02-27 04:15
- 2025-02-27 03:32
Cytokinetics: Q4 Earnings Snapshot(Yahoo Finance)
- 2025-02-27 03:00
- 2025-02-25 18:15
- 2025-02-23 00:34
- 2025-02-19 23:10
- 2025-02-19 21:01
- 2025-02-19 03:00
- 2025-02-13 16:00
- 2025-02-13 07:56
- 2025-02-13 07:56
- 2025-02-13 03:00
- 2025-02-11 07:30
Cytokinetics Names Robert E. Landry to Board of Directors(GlobeNewswire)
- 2025-02-10 18:30
Cytokinetics Names Robert E. Landry to Board of Directors(Globenewswire)
- 2025-02-08 09:05
- 2025-02-07 08:29
- 2025-02-05 16:00
- 2025-02-05 09:16
- 2025-02-05 03:00
- 2025-02-04 19:00
CYTK: What does Argus have to say about CYTK?(Argus Research)
- 2025-02-04 16:00
- 2025-02-04 03:00
- 2025-01-30 09:55
- 2025-01-30 07:30
- 2025-01-29 18:30
- 2025-01-29 12:02
- 2025-01-28 19:00
CYTK: Raising target price to $39.00(Argus Research)
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.